Literature DB >> 11701665

The human homolog of Diminuto/Dwarf1 gene (hDiminuto): a novel ACTH-responsive gene overexpressed in benign cortisol-producing adrenocortical adenomas.

D Sarkar1, T Imai, F Kambe, A Shibata, S Ohmori, A Siddiq, S Hayasaka, H Funahashi, H Seo.   

Abstract

To elucidate the molecular mechanism of the pathogenesis of benign functioning adrenocortical adenomas causing Cushing's syndrome, we employed suppression PCR-based cDNA subtractive hybridization to identify novel genes that are differentially expressed in the adenoma. In this report we describe the adenoma-specific overexpression of the human homolog of the Diminuto/Dwarf1 (hDiminuto) gene. Northern blot analysis revealed that hDiminuto mRNA was overexpressed in the adenoma tissue of 14 patients with Cushing's syndrome in comparison to the adjacent nontumorous adrenal gland. In situ hybridization using hDiminuto cRNA probe showed its abundant expression in the tumor cells, whereas the nontumorous cells showed a low level of expression. As the atrophic adjacent gland may not represent the normal architecture, we examined the expression pattern of hDiminuto mRNA in normal human adrenal cortex. In situ hybridization revealed that it was expressed in all layers of the normal adrenal cortex. In situ apoptosis detection by the TUNEL method revealed that a low level of hDiminuto expression in the atrophic, adjacent gland was associated with numerous TUNEL-positive cells in all layers of cortex. In contrast almost no apoptotic cell was detected in the tumor or in the normal adrenal cortex where hDiminuto expression was abundant. These results are compatible with a recent report that hDiminuto acts as an antiapoptotic factor in neurons. The expression of hDiminuto in the normal adrenal cortex was most abundant in the zona fasciculata, suggesting its possible regulation by ACTH/cAMP. Indeed, forskolin treatment of H295R human adrenocortical cells resulted in a significant induction of the mRNA in a time- and dose-dependent manner. To further demonstrate the physiological regulation, an in vivo experiment was carried out in dexamethasone-treated rats. ACTH administration to these rats increased the mRNA expression. These results led us to speculate that the overexpression of hDiminuto in the adenoma could be due to the abundant expression of ACTH receptor, as we previously described. Diminuto is involved in steroid synthesis and cell elongation in plants. We, therefore, hypothesize that hDiminuto might be involved in the molecular events of adrenocortical tumorigenesis by facilitating steroid synthesis and cell growth.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11701665     DOI: 10.1210/jcem.86.11.8032

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  12 in total

Review 1.  Seladin-1 as a target of estrogen receptor activation in the brain: a new gene for a rather old story?

Authors:  A Peri; G Danza; M Serio
Journal:  J Endocrinol Invest       Date:  2005-03       Impact factor: 4.256

Review 2.  Neuroprotective effects of estrogens: the role of cholesterol.

Authors:  A Peri
Journal:  J Endocrinol Invest       Date:  2015-06-18       Impact factor: 4.256

3.  Adrenal incidentaloma: review of 197 patients and report of a drug-related false-positive urinary normetanephrine result.

Authors:  Takahiro Ito; Tsuneo Imai; Toyone Kikumori; Arihiro Shibata; Takao Horiba; Hironobu Kobayashi; Masataka Sawaki; Reiko Watanabe; Akimasa Nakao; Tetsuya Kiuchi
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

4.  Seladin-1 expression is regulated by promoter methylation in adrenal cancer.

Authors:  Lisa Simi; Francesca Malentacchi; Paola Luciani; Stefania Gelmini; Cristiana Deledda; Rosaria Arvia; Massimo Mannelli; Alessandro Peri; Claudio Orlando
Journal:  BMC Cancer       Date:  2010-05-13       Impact factor: 4.430

5.  Altered expression of 3-betahydroxysterol delta-24-reductase/selective Alzheimer's disease indicator-1 gene in Huntington's disease models.

Authors:  Athina Samara; Mariarita Galbiati; Paola Luciani; Cristiana Deledda; Elio Messi; Alessandro Peri; Roberto Maggi
Journal:  J Endocrinol Invest       Date:  2014-06-11       Impact factor: 4.256

6.  Immunohistochemical expression of osteopontin in gastric cancer.

Authors:  Motohiro Imano; Takao Satou; Tatsuki Itoh; Kenichi Sakai; Eizaburo Ishimaru; Atsushi Yasuda; Ying-Feng Peng; Masayuki Shinkai; Fumiharu Akai; Takushi Yasuda; Haruhiko Imamoto; Kiyokata Okuno; Hiroyuki Ito; Hitoshi Shiozaki; Harumasa Ohyanagi
Journal:  J Gastrointest Surg       Date:  2009-07-07       Impact factor: 3.452

7.  The mechanism of the effect of U18666a on blocking the activity of 3β-hydroxysterol Δ-24-reductase (DHCR24): molecular dynamics simulation study and free energy analysis.

Authors:  Xiaoping Quan; Xiuqiang Chen; Deliang Sun; Bo Xu; Linlin Zhao; Xiaoqian Shi; Hongsheng Liu; Bing Gao; Xiuli Lu
Journal:  J Mol Model       Date:  2016-01-27       Impact factor: 1.810

8.  Promoter analysis of the DHCR24 (3β-hydroxysterol Δ(24)-reductase) gene: characterization of SREBP (sterol-regulatory-element-binding protein)-mediated activation.

Authors:  Lidia A Daimiel; María E Fernández-Suárez; Sara Rodríguez-Acebes; Lorena Crespo; Miguel A Lasunción; Diego Gómez-Coronado; Javier Martínez-Botas
Journal:  Biosci Rep       Date:  2012-12-06       Impact factor: 3.840

9.  3 β-hydroxysteroid-Δ 24 reductase (DHCR24) protects neuronal cells from apoptotic cell death induced by endoplasmic reticulum (ER) stress.

Authors:  Xiuli Lu; Yang Li; Weiqi Wang; Shuchao Chen; Ting Liu; Dan Jia; Xiaoping Quan; Deliang Sun; Alan K Chang; Bing Gao
Journal:  PLoS One       Date:  2014-01-29       Impact factor: 3.240

10.  Involvement of Seladin-1 in goniothalamin-induced apoptosis in urinary bladder cancer cells.

Authors:  Heng Kai Yen; Afifah-Radiah Fauzi; Laily Bin Din; Valerie J McKelvey-Martin; Chan Kok Meng; Salmaan Hussain Inayat-Hussain; Nor Fadilah Rajab
Journal:  BMC Complement Altern Med       Date:  2014-08-09       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.